Analyst Ratings for Salix Pharmaceuticals (SLXP) [Buys]
SLXP Rating Summary
SLXP Price Target Summary
Overall Rating:
NEUTRAL
Rating Trend:
Avg. $ Target:
$52.29 (-11.8%)
Avg. $ Target:
$52.29 (-11.8%)
| Date | Firm | Type | Rating (Past) |
PT (Past) |
Start $ | End $ | % Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 1/11/2013 | RBC Capital | New Coverage | Outperform (N/A) |
53.00 (N/A) |
45.59 | 59.28 | 30.03% | Details |
| 11/30/2012 | Mizuho Securities | New Coverage | Outperform (N/A) |
60.00 (N/A) |
41.26 | 59.28 | 43.67% | Details |
| 8/9/2012 | Cantor Fitzgerald » Updated 8/14/2012 |
Upgrade | Buy (Hold) |
60.00 (N/A) |
44.99 | 59.28 | 31.76% | Details |
| 9/23/2011 | Caris & Co. | New Coverage | Buy (N/A) |
53.00 (N/A) |
26.18 | 59.28 | 126.43% | Details |
| 8/10/2011 | Jefferies » Updated 8/9/2012 |
Upgrade | Buy (N/A) |
58.00 (63.00) |
31.99 | 59.28 | 85.31% | Details |
| 7/5/2011 | Duncan Williams | Upgrade | Buy (N/A) |
N/A (N/A) |
39.37 | 59.28 | 50.57% | Details |
| 6/24/2011 | Susquehanna | New Coverage | Positive (N/A) |
N/A (N/A) |
38.70 | 59.28 | 53.18% | Details |
| 4/29/2011 | Brean Capital » Updated 11/10/2011 |
New Coverage | Buy (N/A) |
50.00 (N/A) |
38.34 | 59.28 | 54.62% | Details |
| 4/28/2011 | William Blair | New Coverage | Outperform (N/A) |
N/A (N/A) |
37.83 | 59.28 | 56.7% | Details |
| 12/14/2010 | Credit Suisse » Updated 5/9/2011 |
New Coverage | Outperform (N/A) |
N/A (N/A) |
43.33 | 59.28 | 36.81% | Details |
